Karyopharm Therapeutics, Inc. KPTI 深 沪
已收盘 10-30 16:00:00 美东时间
0.662
-0.218
-24.76%
华盛通- 最 高0.902
- 今 开0.902
- 成交量 350.67万股
- 最 低 0.5842
- 昨 收 0.8798
- 总市值 1.50万
- 52周最高 10.99
- 市盈率 静 --
- 换手率 15460.86%
- 52周最低 0.31
- 委 比 0.00%
- 总股本 2.27万
- 历史最高 735.075
- 量 比 0.26
- 振 幅 36.12%
- 历史最低 0.31
- 每 手 1
- 风险率 3.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Karyopharm Therapeutics Extends Forbearance Period End Date To November 1, 2026
As previously disclosed in the Current Reports on Form 8-K filed by Karyopharm Therapeutics Inc. (the "Company") on September 11, 2026 and October 14, 2026, the Company entered into a Forbearance Agreement and Limited Waiver to Indentures, dated September 10, 2026 (the "Forbearance Agreement"), and ...
10-23 04:47
Karyopharm Therapeutics Extends Forbearance Period To October 15
As previously disclosed in the Current Report on Form 8-K filed by Karyopharm Therapeutics Inc. (the "Company") on September 11, 2026, the Company entered into a Forbearance Agreement and Limited Waiver to Indentures, dated September 10, 2026 (the "Forbearance Agreement"). On October 13, 2026, in ac...
10-14 19:34
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Oct. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...
10-02 04:05
Karyopharm Issues Convertible Preferred Stock, Alters Capital Structure
The latest announcement is out from Karyopharm Therapeutics ( ($KPTI) ). On Sep...
09-19 04:36
Karyopharm Faces Liquidity Crisis Under Forbearance Agreement
Karyopharm Therapeutics ( ($KPTI) ) has shared an announcement. On September 10...
09-11 20:18
德琪医药合作伙伴Karyopharm向美国FDA提交塞利尼索联合芦可替尼治疗骨髓...
德琪医药合作伙伴Karyopharm Therapeutics Inc.（纳斯达克代码：KPTI）近日宣布，公司已向美国食品药品监督管理局（FDA）提交补充新药...
09-02 09:59
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Sept. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that th...
09-02 04:05
Karyopharm Therapeutics Submits sNDA To FDA Seeking Accelerated Approval For XPOVIO In Combination With Ruxolitinib For Patients With Myelofibrosis
– sNDA Submitted under the Accelerated Approval Pathway; Priority Review Requested – NEWTON, Mass., Aug. 31, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has submitted a supplemen...
08-31 19:32
Karyopharm Therapeutics Affirms FY2026 Sales Guidance of $130.000M-$150.000M vs $133.736M Est
Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2026 sales outlook from $130.000 million-$150.000 million to $130.000 million-$150.000 million vs $133.736 million estimate.
08-13 19:32
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Zenas BioPharma reported financial results for Q2 2026 and provided updates on its pipeline. The FDA accepted the BLA for obexelimab to treat IgG4-RD with a PDUFA date of May 27, 2027. New bioequivalence data for obexelimab's delivery methods were confirmed. Phase 2 SunStone SLE trial results are expected in Q4 2026. ZB021's Phase 1 trial is ongoing, with initial data anticipated by year-end. Four abstracts for orelabrutinib were accepted for MST...
08-13 11:00
